Agios Q3 PYRUKYND rev $12.9M (+44% YoY); net loss $103.4M; thalassemia PDUFA Dec 7

AGIOS PHARMACEUTICALS, INC.

2025-Q3 EPS reported -$5.27 revenue$34,061,000

Q3 PYRUKYND net revenue $12.9M (+44% YoY vs $9.0M); 149 U.S. patients on therapy.
Net loss $103.4M in Q3 2025 vs net income $947.9M in Q3 2024 (prior-year milestone payments).
Cash $1.3B; PDUFA goal date Dec 7, 2025 for PYRUKYND sNDA in thalassemia.
CHMP positive opinion for PYRUKYND in thalassemia; EC decision expected early 2026.
RISE UP Phase 3 sickle cell disease topline results by year-end; tebapivat Phase 2b topline early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.